GlassScriptPhysician profile
Melody Leigh Smith
NPI 1952734162
$5,275.46
in general payments reported to CMS, 2019-2025
24 companies · $3,545 in 2025
The $3,545 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,060 · 2022: $157 · 2023: $131 · 2024: $383 · 2025: $3,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984 · Travel and Lodging: $906 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.78 |
| Travel and Lodging | $905.92 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,463.85 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $901.43 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Allergan, INC. | $661.25 | 2021 | |
| Genzyme Corporation | $351.41 | 2025 | |
| Harmony Biosciences LLC | $316.92 | 2024-2025 | |
| Insmed, INC. | $316.40 | 2025 | Arikayce, Brinsupri |
| Abbvie INC. | $216.49 | 2021-2025 | |
| Grifols USA, LLC | $144.06 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $138.15 | 2022-2024 | Mounjaro |
| Pfizer INC. | $97.07 | 2021 | |
| Merck Sharp & Dohme LLC | $90.00 | 2024-2025 | Winrevair |
| Amgen INC. | $85.39 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Indivior INC. | $67.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.41 | 2025 | Glassia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.19 | 2023-2025 | Jascayd, Cyltezo |
| United Therapeutics Corporation | $49.64 | 2025 | Tyvaso |
| Verona Pharma, INC. | $48.48 | 2025 | Ohtuvayre |
| Baxter Healthcare | $47.58 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Biohaven Pharmaceuticals, INC. | $21.69 | 2021 | |
| Novo Nordisk INC | $19.33 | 2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $16.51 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.49 | 2025 | Nuzyra |
| Genentech USA, INC. | $4.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.